Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine EraSara de Miguel, José Yuste, Mirian Domenech et al.|Clinical Infectious Diseases|2020Cited by 113
Auranofin efficacy against MDR<i>Streptococcus pneumoniae</i>and<i>Staphylococcus aureus</i>infectionsLeire Aguinagalde, José-María Sánchez-Puelles, José Yuste et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 69
Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)Covadonga Pérez-García, José Yuste, Julio Sempere et al.|Journal of Infection|2024Cited by 61
Emergence of Amoxicillin-Resistant Variants of Spain9V-ST156 Pneumococci Expressing Serotype 11A Correlates with Their Ability to Evade the Host Immune ResponseLeire Aguinagalde, José Yuste, Bruno Corsini et al.|PLoS ONE|2015Cited by 51
Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in SpainAída González-Díaz, Carmen Ardanuy, Jordi Cámara et al.|Clinical Microbiology and Infection|2019Cited by 51